Show simple item record

dc.rights.licenseopenen_US
hal.structure.identifierCIC - Bordeaux
dc.contributor.authorBOSCO-LEVY, Pauline
dc.contributor.authorDEBOUVERIE, M.
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorBROCHET, Bruno
dc.contributor.authorLOUAPRE, C.
dc.contributor.authorMAILLART, E.
dc.contributor.authorHEINZLEF, O.
hal.structure.identifierCIC Bordeaux
dc.contributor.authorLIGNOT, Severine
hal.structure.identifierCIC - Bordeaux
dc.contributor.authorDIEZ, Pauline
hal.structure.identifierCIC - Bordeaux
dc.contributor.authorABOUELFATH, Abdelilah
hal.structure.identifierCIC - Bordeaux
dc.contributor.authorLASSALLE, Regis
hal.structure.identifierCIC - Bordeaux
dc.contributor.authorBLIN, Patrick
hal.structure.identifierCIC - Bordeaux
dc.contributor.authorDROZ-PERROTEAU, Cecile
dc.date.accessioned2022-03-28T15:08:35Z
dc.date.available2022-03-28T15:08:35Z
dc.date.issued2021-03
dc.identifier.issn1365-2125en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/136544
dc.description.abstractEnAims : To assess the effectiveness of dimethyl fumarate (DMF) on annual rate of relapse subject to treatment (ARRt) and disability progression in multiple sclerosis (MS) compared to injectable immunomodulators (IMM), teriflunomide (TERI) and fingolimob (FTY), in real-life setting. Methods : A population-based cohort study was conducted using data of the French nationwide claims database, SNDS. All patients initiating IMM, TERI, FTY or DMF between 1 July 2015 and 12 December 2017, with 4.5 years of database history and 1–3.5 years of follow-up were included in this study. DMF patients were 1:1 matched to IMM, TERI or FTY using a high dimensional propensity score. Negative binomial regression and a logistic regression model were used to estimate the relative risk (RR ± [95% CI]) of ARRt and the odds ratio (OR ± [95% CI]) of disability progression, respectively. Results : Overall, 9304 subjects were identified: 29.0% initiated DMF, 33.2% TERI, 5.6% FTY and 32.2% an IMM. The matched cohorts consisted of 1779 DMF-IMM patients, 1679 DMF-TERI patients, and 376 DMF-FTY patients. DMF significantly reduced ARRt compared to IMM (RR 0.72 [0.61–0.86]) and TERI (0.81 [0.68–0.96]) and did not show any significant difference when compared with FTY. The risk of the progression of MS-specific disability was not significantly different for any matched cohorts. Conclusion : DMF is associated with lower risk of treated relapse for patients with RRMS than other first-line RRMS agents (TERI and IIM).
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enCohort study
dc.subject.enDimethylfumarate
dc.subject.enEffectiveness
dc.subject.enHigh dimensional propensity score
dc.subject.enMultiple sclerosis
dc.subject.enRelapse
dc.title.enComparative effectiveness of dimethyl fumarate in multiple sclerosis
dc.title.alternativeBr J Clin Pharmacolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/bcp.15071en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed34505304en_US
bordeaux.journalBritish Journal of Clinical Pharmacologyen_US
bordeaux.hal.laboratoriesNeurocentre Magendie - UMR-S 1215en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDBiogenen_US
bordeaux.identifier.funderIDUniversité de Bordeauxen_US
hal.identifierhal-03622107
hal.version1
hal.date.transferred2022-03-28T15:08:38Z
hal.exporttrue
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British%20Journal%20of%20Clinical%20Pharmacology&rft.date=2021-03&rft.eissn=1365-2125&rft.issn=1365-2125&rft.au=BOSCO-LEVY,%20Pauline&DEBOUVERIE,%20M.&BROCHET,%20Bruno&LOUAPRE,%20C.&MAILLART,%20E.&rft.genre=article


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record